Dupilumab for allergic contact dermatitis and implications for patch testing: Irreconcilable differences - 19/08/20

| Funding sources: None. |
|
| Conflicts of interest: Dr Cohen is a consultant for and receives honorarium from Ferndale Laboratories, Asana, Medimetriks, UCB, Cutanea, Ferrer, Celgene, Dermavant, FSJ, and FIDE (FIDE receives industry sponsorship from AbbVie, Almirall, Amgen, Bausch and Lomb, Bristol-Myers Squibb, Celgene Dermavant, Dermira, Janssen, Kyowa Hakko Kirin, LEO Pharma, Lilly, Novartis, Ortho Dermatologics, Pfizer, Sanofi Genzyme, Sun Pharma, UCB, and Valeant), holds stock or stock options from Dermira, Medimetriks, Brickell Biotech, Kadmon, and Evommune, and is on the board of directors of Kadmon, Evommune, and Dermira (past). Payal Shah and Drs Milam and Lo Sicco have no conflicts of interest to disclose. |
|
| IRB approval status: Not applicable. |
|
| Reprints not available from the authors. |
Vol 83 - N° 3
P. e215-e216 - septembre 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
